Evidence map›Paper›PMID 32328307›Full record

ArticleInternational journal of nephrology2020

Gum Arabic (

Nour Elkhair Ali, Lamis AbdelGadir Kaddam, Suad Yousif Alkarib, Babikir Gabir Kaballo, Sami Ahmed Khalid, Abdalazim Higawee, Alaa AbdElhabib, Alaa AlaaAldeen, Aled O Phillips, Amal Mahmoud Saeed

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in International journal of nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03214692 naunknown statusnot on this map

Potential Role of Gum Arabic as Antioxidant and Anti-inflammatory Agent in Hemodialysis Patients

TypeinterventionalSponsorLamis KaddamRan2017 to 2017Enrolled50ConditionsEnd-Stage Renal DiseaseArmsGum Arabic
NCT04381871 phase2 / phase3unknown statusnot on this map

Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan

TypeinterventionalSponsorAl-Neelain UniversityRan2020 to 2020Enrolled110ConditionsCOVID 19ArmsAcacia Senegal, Pectin
NCT06836206 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of Gum Arabic (GA) on Adult Dialysis Patients in Abu Dhabi: A Prospective Randomized-controlled Trial (The GADAD Study)

TypeinterventionalSponsorAbu Dhabi Health Services CompanyRan2025 to 2026Enrolled40ConditionsEnd Stage Renal Disease (ESRD)ArmsGum Arabic, Water
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Therapeutic Potential of Gum Arabic (Journal of clinical medicine · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Ca' Granda,Molecules (Basel, Switzerland) · 2021
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Nour Elkhair AliDepartment of Physiology, Faculty of Medicine, Alneelain University, Khartoum, Sudan.
Lamis AbdelGadir KaddamDepartment of Physiology, Faculty of Medicine, Alneelain University, Khartoum, Sudan.ORCID https://orcid.org/0000-0002-1083-4514
Suad Yousif AlkaribDepartment of Pharmaceutics, College of Pharmacy, Karary University, Khartoum, Sudan.
Babikir Gabir KaballoNephrology Unit, Military Hospital Omdurman, Sudan.
Sami Ahmed KhalidFaculty of Pharmacy, University of Science & Technology, Omdurman, Sudan.
Abdalazim HigaweeNephrology Unit, Military Hospital Omdurman, Sudan.
Alaa AbdElhabibNephrology Unit, Military Hospital Omdurman, Sudan.
Alaa AlaaAldeenNephrology Unit, Military Hospital Omdurman, Sudan.
Aled O PhillipsInstitute of Nephrology, Cardiff University School of Medicine, Cardiff, UK.
Amal Mahmoud SaeedDepartment of Physiology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Al-Neelain University · SDKarary University · SDCardiff University · GBUniversity of Khartoum · SDUniversity of Science and Technology Omdurman · SD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxidative processes might increase in patients with end-stage renal disease (ESRD) according to the current literature. Oxidative stress (OS) is a risk factor of atherosclerosis and cardiovascular complications, which are major causes of mortality among ESRD patients. Haemodialysis (HD) is life-saving procedure, nevertheless it is an active chronic inflammatory status that could augment cardiovascular disease and increase mortality. Gum Arabic (GA) has been claimed to act as an antioxidant and anti-inflammatory agent in experimental studies and clinical trials. Therefore, we assumed GA supplementation among haemodialysis patients would reduce oxidative stress and consequently reduce the state of chronic inflammatory activation associated with haemodialysis.

methodsForty end-stage renal failure (ESRF) patients aged 18-80 years who were on regular haemodialysis in Arif Renal Center, Omdurman, Sudan, were recruited. All recruited patients met the inclusion criteria and signed informed consent prior to enrolment. The patients received 30 g/day of GA for 12 weeks. C-reactive protein (CRP) and complete blood count (CBC) were measured as baseline and monthly. Total antioxidant capacity (TAC) and oxidative stress marker malondialdehyde (MDA) levels were measured before and after GA intake. Ethical approval from the National Medicines and Poisons Board was obtained.

resultsGum Arabic significantly augmented total antioxidant capacity level (

conclusionsGA has revealed potent antioxidative and anti-inflammatory properties in haemodialysis patients. Oral digestion of GA (30 g/day) decreased oxidative stress and inflammatory markers among haemodialysis patients. Trial registration. ClinicalTrials.gov Identifier: NCT03214692, registered 11 July 2017 (prospective registration).

Identifiers

PMID32328307
PMCPMC7171621
OpenAlexW3015238226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.